Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Acumapimod
Cat. No.:
OB0225LY-0347
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Product Overview
Description:
Acumapimod is a compound that selectively inhibits p38 MAPK and involves multiple signaling pathways.
Synonym:
BCT-197; 836683-15-9; 3-(5-Amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide; 3-(5-Amino-4-(3-cyanobenzoyl)pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide; 3-[5-Amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
CAS No.:
836683-15-9
Compound CID:
11338127
Formula:
C22H19N5O2
Formula Weight:
385.42
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Acumapimod can be used for inflammatory metabolic pathway studies.
Library Information
Targets:
MAPK family
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-5
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 129.73 mM
